

Global Nucleotide-based Therapeutics Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/GB9A17740A80EN.html>

Date: November 2023

Pages: 174

Price: US\$ 4,480.00 (Single User License)

ID: GB9A17740A80EN

Abstracts

The global Nucleotide-based Therapeutics market size is expected to reach \$ 84010 million by 2029, rising at a market growth of 3.6% CAGR during the forecast period (2023-2029).

The Nucleic Acid-Based Therapeutics Drug Market is driven by the promising potential of nucleic acid-based therapies in treating various genetic and acquired diseases, including genetic disorders, cancer, and infectious diseases. These innovative drugs utilize nucleic acids, such as DNA or RNA, to modify or regulate gene expression, correct genetic mutations, or target specific disease-associated genes. As the understanding of genomics and molecular biology advances, and personalized medicine gains traction, the demand for nucleic acid-based therapeutics continues to grow. Innovations in drug development, delivery systems, and gene editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to address delivery and stability issues, ensure long-term safety and efficacy, and navigate regulatory complexities and patient acceptance. Overcoming technical and scientific hurdles, optimizing drug delivery methods, and addressing concerns about off-target effects are ongoing challenges. Additionally, the market faces competition from conventional therapies and the need for continuous research and development to unlock the full therapeutic potential of nucleic acid-based drugs. Striking a balance between providing safe, effective, and accessible nucleic acid-based therapeutics while addressing scientific and regulatory challenges is essential for the continued growth of the Nucleic Acid-Based Therapeutics Drug Market.

Nucleotide-based therapeutics offer huge potential to specifically modulate cellular pathways in ways not previously possible. These therapies include all nucleic-acid-based approaches that work inside cells to affect gene expression – the genetic

blueprint of disease – to ultimately change protein expression and potentially alter the course of disease.

This report studies the global Nucleotide-based Therapeutics demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Nucleotide-based Therapeutics, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Nucleotide-based Therapeutics that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Nucleotide-based Therapeutics total market, 2018-2029, (USD Million)

Global Nucleotide-based Therapeutics total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Nucleotide-based Therapeutics total market, key domestic companies and share, (USD Million)

Global Nucleotide-based Therapeutics revenue by player and market share 2018-2023, (USD Million)

Global Nucleotide-based Therapeutics total market by Type, CAGR, 2018-2029, (USD Million)

Global Nucleotide-based Therapeutics total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Nucleotide-based Therapeutics market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech and Pfizer, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Nucleotide-based Therapeutics market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Nucleotide-based Therapeutics Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global Nucleotide-based Therapeutics Market, Segmentation by Type

Antisense Oligonucleotides (ASO)

siRNA

mRNA

Global Nucleotide-based Therapeutics Market, Segmentation by Application

Neuromuscular Diseases

hATTR

COVID-19

Other

Companies Profiled:

Sarepta Therapeutics

Ionis Pharmaceuticals

Anylam

Biogen

Nippon Shinyaku

Sobi

Novartis

BioNTech

Pfizer

Moderna Therapeutics

Jazz Pharmaceuticals

CureVac

Regulus Therapeutics

ProQR

Secarna

MiNA Therapeutics

Sylentis

Arrowhead

Silence Therapeutics

Dicerna

Key Questions Answered

1. How big is the global Nucleotide-based Therapeutics market?
2. What is the demand of the global Nucleotide-based Therapeutics market?
3. What is the year over year growth of the global Nucleotide-based Therapeutics market?
4. What is the total value of the global Nucleotide-based Therapeutics market?
5. Who are the major players in the global Nucleotide-based Therapeutics market?

Contents

1 SUPPLY SUMMARY

- 1.1 Nucleotide-based Therapeutics Introduction
- 1.2 World Nucleotide-based Therapeutics Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Nucleotide-based Therapeutics Total Market by Region (by Headquarter Location)
 - 1.3.1 World Nucleotide-based Therapeutics Market Size by Region (2018-2029), (by Headquarter Location)
 - 1.3.2 United States Nucleotide-based Therapeutics Market Size (2018-2029)
 - 1.3.3 China Nucleotide-based Therapeutics Market Size (2018-2029)
 - 1.3.4 Europe Nucleotide-based Therapeutics Market Size (2018-2029)
 - 1.3.5 Japan Nucleotide-based Therapeutics Market Size (2018-2029)
 - 1.3.6 South Korea Nucleotide-based Therapeutics Market Size (2018-2029)
 - 1.3.7 ASEAN Nucleotide-based Therapeutics Market Size (2018-2029)
 - 1.3.8 India Nucleotide-based Therapeutics Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 Nucleotide-based Therapeutics Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Nucleotide-based Therapeutics Major Market Trends

2 DEMAND SUMMARY

- 2.1 World Nucleotide-based Therapeutics Consumption Value (2018-2029)
- 2.2 World Nucleotide-based Therapeutics Consumption Value by Region
 - 2.2.1 World Nucleotide-based Therapeutics Consumption Value by Region (2018-2023)
 - 2.2.2 World Nucleotide-based Therapeutics Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Nucleotide-based Therapeutics Consumption Value (2018-2029)
- 2.4 China Nucleotide-based Therapeutics Consumption Value (2018-2029)
- 2.5 Europe Nucleotide-based Therapeutics Consumption Value (2018-2029)
- 2.6 Japan Nucleotide-based Therapeutics Consumption Value (2018-2029)
- 2.7 South Korea Nucleotide-based Therapeutics Consumption Value (2018-2029)
- 2.8 ASEAN Nucleotide-based Therapeutics Consumption Value (2018-2029)
- 2.9 India Nucleotide-based Therapeutics Consumption Value (2018-2029)

3 WORLD NUCLEOTIDE-BASED THERAPEUTICS COMPANIES COMPETITIVE ANALYSIS

- 3.1 World Nucleotide-based Therapeutics Revenue by Player (2018-2023)
- 3.2 Industry Rank and Concentration Rate (CR)
 - 3.2.1 Global Nucleotide-based Therapeutics Industry Rank of Major Players
 - 3.2.2 Global Concentration Ratios (CR4) for Nucleotide-based Therapeutics in 2022
 - 3.2.3 Global Concentration Ratios (CR8) for Nucleotide-based Therapeutics in 2022
- 3.3 Nucleotide-based Therapeutics Company Evaluation Quadrant
- 3.4 Nucleotide-based Therapeutics Market: Overall Company Footprint Analysis
 - 3.4.1 Nucleotide-based Therapeutics Market: Region Footprint
 - 3.4.2 Nucleotide-based Therapeutics Market: Company Product Type Footprint
 - 3.4.3 Nucleotide-based Therapeutics Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: Nucleotide-based Therapeutics Revenue Comparison (by Headquarter Location)
 - 4.1.1 United States VS China: Nucleotide-based Therapeutics Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
 - 4.1.2 United States VS China: Nucleotide-based Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
- 4.2 United States Based Companies VS China Based Companies: Nucleotide-based Therapeutics Consumption Value Comparison
 - 4.2.1 United States VS China: Nucleotide-based Therapeutics Consumption Value Comparison (2018 & 2022 & 2029)
 - 4.2.2 United States VS China: Nucleotide-based Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based Nucleotide-based Therapeutics Companies and Market Share, 2018-2023
 - 4.3.1 United States Based Nucleotide-based Therapeutics Companies, Headquarters (States, Country)
 - 4.3.2 United States Based Companies Nucleotide-based Therapeutics Revenue,

(2018-2023)

4.4 China Based Companies Nucleotide-based Therapeutics Revenue and Market Share, 2018-2023

4.4.1 China Based Nucleotide-based Therapeutics Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023)

4.5 Rest of World Based Nucleotide-based Therapeutics Companies and Market Share, 2018-2023

4.5.1 Rest of World Based Nucleotide-based Therapeutics Companies, Headquarters (States, Country)

4.5.2 Rest of World Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

5.1 World Nucleotide-based Therapeutics Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 Antisense Oligonucleotides (ASO)

5.2.2 siRNA

5.2.3 mRNA

5.3 Market Segment by Type

5.3.1 World Nucleotide-based Therapeutics Market Size by Type (2018-2023)

5.3.2 World Nucleotide-based Therapeutics Market Size by Type (2024-2029)

5.3.3 World Nucleotide-based Therapeutics Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

6.1 World Nucleotide-based Therapeutics Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Neuromuscular Diseases

6.2.2 hATTR

6.2.3 COVID-19

6.2.4 Other

6.2.5 Other

6.3 Market Segment by Application

6.3.1 World Nucleotide-based Therapeutics Market Size by Application (2018-2023)

- 6.3.2 World Nucleotide-based Therapeutics Market Size by Application (2024-2029)
- 6.3.3 World Nucleotide-based Therapeutics Market Size by Application (2018-2029)

7 COMPANY PROFILES

7.1 Sarepta Therapeutics

- 7.1.1 Sarepta Therapeutics Details
- 7.1.2 Sarepta Therapeutics Major Business
- 7.1.3 Sarepta Therapeutics Nucleotide-based Therapeutics Product and Services
- 7.1.4 Sarepta Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 7.1.5 Sarepta Therapeutics Recent Developments/Updates
- 7.1.6 Sarepta Therapeutics Competitive Strengths & Weaknesses

7.2 Ionis Pharmaceuticals

- 7.2.1 Ionis Pharmaceuticals Details
- 7.2.2 Ionis Pharmaceuticals Major Business
- 7.2.3 Ionis Pharmaceuticals Nucleotide-based Therapeutics Product and Services
- 7.2.4 Ionis Pharmaceuticals Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 7.2.5 Ionis Pharmaceuticals Recent Developments/Updates
- 7.2.6 Ionis Pharmaceuticals Competitive Strengths & Weaknesses

7.3 Alnylam

- 7.3.1 Alnylam Details
- 7.3.2 Alnylam Major Business
- 7.3.3 Alnylam Nucleotide-based Therapeutics Product and Services
- 7.3.4 Alnylam Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 7.3.5 Alnylam Recent Developments/Updates
- 7.3.6 Alnylam Competitive Strengths & Weaknesses

7.4 Biogen

- 7.4.1 Biogen Details
- 7.4.2 Biogen Major Business
- 7.4.3 Biogen Nucleotide-based Therapeutics Product and Services
- 7.4.4 Biogen Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 7.4.5 Biogen Recent Developments/Updates
- 7.4.6 Biogen Competitive Strengths & Weaknesses

7.5 Nippon Shinyaku

- 7.5.1 Nippon Shinyaku Details

- 7.5.2 Nippon Shinyaku Major Business
- 7.5.3 Nippon Shinyaku Nucleotide-based Therapeutics Product and Services
- 7.5.4 Nippon Shinyaku Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 7.5.5 Nippon Shinyaku Recent Developments/Updates
- 7.5.6 Nippon Shinyaku Competitive Strengths & Weaknesses
- 7.6 Sobi
 - 7.6.1 Sobi Details
 - 7.6.2 Sobi Major Business
 - 7.6.3 Sobi Nucleotide-based Therapeutics Product and Services
 - 7.6.4 Sobi Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.6.5 Sobi Recent Developments/Updates
 - 7.6.6 Sobi Competitive Strengths & Weaknesses
- 7.7 Novartis
 - 7.7.1 Novartis Details
 - 7.7.2 Novartis Major Business
 - 7.7.3 Novartis Nucleotide-based Therapeutics Product and Services
 - 7.7.4 Novartis Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.7.5 Novartis Recent Developments/Updates
 - 7.7.6 Novartis Competitive Strengths & Weaknesses
- 7.8 BioNTech
 - 7.8.1 BioNTech Details
 - 7.8.2 BioNTech Major Business
 - 7.8.3 BioNTech Nucleotide-based Therapeutics Product and Services
 - 7.8.4 BioNTech Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.8.5 BioNTech Recent Developments/Updates
 - 7.8.6 BioNTech Competitive Strengths & Weaknesses
- 7.9 Pfizer
 - 7.9.1 Pfizer Details
 - 7.9.2 Pfizer Major Business
 - 7.9.3 Pfizer Nucleotide-based Therapeutics Product and Services
 - 7.9.4 Pfizer Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.9.5 Pfizer Recent Developments/Updates
 - 7.9.6 Pfizer Competitive Strengths & Weaknesses
- 7.10 Moderna Therapeutics

- 7.10.1 Moderna Therapeutics Details
- 7.10.2 Moderna Therapeutics Major Business
- 7.10.3 Moderna Therapeutics Nucleotide-based Therapeutics Product and Services
- 7.10.4 Moderna Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 7.10.5 Moderna Therapeutics Recent Developments/Updates
- 7.10.6 Moderna Therapeutics Competitive Strengths & Weaknesses
- 7.11 Jazz Pharmaceuticals
 - 7.11.1 Jazz Pharmaceuticals Details
 - 7.11.2 Jazz Pharmaceuticals Major Business
 - 7.11.3 Jazz Pharmaceuticals Nucleotide-based Therapeutics Product and Services
 - 7.11.4 Jazz Pharmaceuticals Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.11.5 Jazz Pharmaceuticals Recent Developments/Updates
 - 7.11.6 Jazz Pharmaceuticals Competitive Strengths & Weaknesses
- 7.12 CureVac
 - 7.12.1 CureVac Details
 - 7.12.2 CureVac Major Business
 - 7.12.3 CureVac Nucleotide-based Therapeutics Product and Services
 - 7.12.4 CureVac Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.12.5 CureVac Recent Developments/Updates
 - 7.12.6 CureVac Competitive Strengths & Weaknesses
- 7.13 Regulus Therapeutics
 - 7.13.1 Regulus Therapeutics Details
 - 7.13.2 Regulus Therapeutics Major Business
 - 7.13.3 Regulus Therapeutics Nucleotide-based Therapeutics Product and Services
 - 7.13.4 Regulus Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.13.5 Regulus Therapeutics Recent Developments/Updates
 - 7.13.6 Regulus Therapeutics Competitive Strengths & Weaknesses
- 7.14 ProQR
 - 7.14.1 ProQR Details
 - 7.14.2 ProQR Major Business
 - 7.14.3 ProQR Nucleotide-based Therapeutics Product and Services
 - 7.14.4 ProQR Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.14.5 ProQR Recent Developments/Updates
 - 7.14.6 ProQR Competitive Strengths & Weaknesses

7.15 Secarna

7.15.1 Secarna Details

7.15.2 Secarna Major Business

7.15.3 Secarna Nucleotide-based Therapeutics Product and Services

7.15.4 Secarna Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

7.15.5 Secarna Recent Developments/Updates

7.15.6 Secarna Competitive Strengths & Weaknesses

7.16 MiNA Therapeutics

7.16.1 MiNA Therapeutics Details

7.16.2 MiNA Therapeutics Major Business

7.16.3 MiNA Therapeutics Nucleotide-based Therapeutics Product and Services

7.16.4 MiNA Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

7.16.5 MiNA Therapeutics Recent Developments/Updates

7.16.6 MiNA Therapeutics Competitive Strengths & Weaknesses

7.17 Sylentis

7.17.1 Sylentis Details

7.17.2 Sylentis Major Business

7.17.3 Sylentis Nucleotide-based Therapeutics Product and Services

7.17.4 Sylentis Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

7.17.5 Sylentis Recent Developments/Updates

7.17.6 Sylentis Competitive Strengths & Weaknesses

7.18 Arrowhead

7.18.1 Arrowhead Details

7.18.2 Arrowhead Major Business

7.18.3 Arrowhead Nucleotide-based Therapeutics Product and Services

7.18.4 Arrowhead Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

7.18.5 Arrowhead Recent Developments/Updates

7.18.6 Arrowhead Competitive Strengths & Weaknesses

7.19 Silence Therapeutics

7.19.1 Silence Therapeutics Details

7.19.2 Silence Therapeutics Major Business

7.19.3 Silence Therapeutics Nucleotide-based Therapeutics Product and Services

7.19.4 Silence Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

7.19.5 Silence Therapeutics Recent Developments/Updates

- 7.19.6 Silence Therapeutics Competitive Strengths & Weaknesses
- 7.20 Dicerna
 - 7.20.1 Dicerna Details
 - 7.20.2 Dicerna Major Business
 - 7.20.3 Dicerna Nucleotide-based Therapeutics Product and Services
 - 7.20.4 Dicerna Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 7.20.5 Dicerna Recent Developments/Updates
 - 7.20.6 Dicerna Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

- 8.1 Nucleotide-based Therapeutics Industry Chain
- 8.2 Nucleotide-based Therapeutics Upstream Analysis
- 8.3 Nucleotide-based Therapeutics Midstream Analysis
- 8.4 Nucleotide-based Therapeutics Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

- 10.1 Methodology
- 10.2 Research Process and Data Source
- 10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Nucleotide-based Therapeutics Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World Nucleotide-based Therapeutics Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World Nucleotide-based Therapeutics Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World Nucleotide-based Therapeutics Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World Nucleotide-based Therapeutics Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Nucleotide-based Therapeutics Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World Nucleotide-based Therapeutics Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World Nucleotide-based Therapeutics Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World Nucleotide-based Therapeutics Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key Nucleotide-based Therapeutics Players in 2022

Table 12. World Nucleotide-based Therapeutics Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global Nucleotide-based Therapeutics Company Evaluation Quadrant

Table 14. Head Office of Key Nucleotide-based Therapeutics Player

Table 15. Nucleotide-based Therapeutics Market: Company Product Type Footprint

Table 16. Nucleotide-based Therapeutics Market: Company Product Application Footprint

Table 17. Nucleotide-based Therapeutics Mergers & Acquisitions Activity

Table 18. United States VS China Nucleotide-based Therapeutics Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China Nucleotide-based Therapeutics Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based Nucleotide-based Therapeutics Companies, Headquarters (States, Country)

Table 21. United States Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Nucleotide-based Therapeutics Revenue Market Share (2018-2023)

Table 23. China Based Nucleotide-based Therapeutics Companies, Headquarters (Province, Country)

Table 24. China Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Nucleotide-based Therapeutics Revenue Market Share (2018-2023)

Table 26. Rest of World Based Nucleotide-based Therapeutics Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Nucleotide-based Therapeutics Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Nucleotide-based Therapeutics Revenue Market Share (2018-2023)

Table 29. World Nucleotide-based Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Nucleotide-based Therapeutics Market Size by Type (2018-2023) & (USD Million)

Table 31. World Nucleotide-based Therapeutics Market Size by Type (2024-2029) & (USD Million)

Table 32. World Nucleotide-based Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World Nucleotide-based Therapeutics Market Size by Application (2018-2023) & (USD Million)

Table 34. World Nucleotide-based Therapeutics Market Size by Application (2024-2029) & (USD Million)

Table 35. Sarepta Therapeutics Basic Information, Area Served and Competitors

Table 36. Sarepta Therapeutics Major Business

Table 37. Sarepta Therapeutics Nucleotide-based Therapeutics Product and Services

Table 38. Sarepta Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. Sarepta Therapeutics Recent Developments/Updates

Table 40. Sarepta Therapeutics Competitive Strengths & Weaknesses

Table 41. Ionis Pharmaceuticals Basic Information, Area Served and Competitors

Table 42. Ionis Pharmaceuticals Major Business

Table 43. Ionis Pharmaceuticals Nucleotide-based Therapeutics Product and Services

Table 44. Ionis Pharmaceuticals Nucleotide-based Therapeutics Revenue, Gross

Margin and Market Share (2018-2023) & (USD Million)

Table 45. Ionis Pharmaceuticals Recent Developments/Updates

Table 46. Ionis Pharmaceuticals Competitive Strengths & Weaknesses

Table 47. Alnylam Basic Information, Area Served and Competitors

Table 48. Alnylam Major Business

Table 49. Alnylam Nucleotide-based Therapeutics Product and Services

Table 50. Alnylam Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 51. Alnylam Recent Developments/Updates

Table 52. Alnylam Competitive Strengths & Weaknesses

Table 53. Biogen Basic Information, Area Served and Competitors

Table 54. Biogen Major Business

Table 55. Biogen Nucleotide-based Therapeutics Product and Services

Table 56. Biogen Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 57. Biogen Recent Developments/Updates

Table 58. Biogen Competitive Strengths & Weaknesses

Table 59. Nippon Shinyaku Basic Information, Area Served and Competitors

Table 60. Nippon Shinyaku Major Business

Table 61. Nippon Shinyaku Nucleotide-based Therapeutics Product and Services

Table 62. Nippon Shinyaku Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 63. Nippon Shinyaku Recent Developments/Updates

Table 64. Nippon Shinyaku Competitive Strengths & Weaknesses

Table 65. Sobi Basic Information, Area Served and Competitors

Table 66. Sobi Major Business

Table 67. Sobi Nucleotide-based Therapeutics Product and Services

Table 68. Sobi Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 69. Sobi Recent Developments/Updates

Table 70. Sobi Competitive Strengths & Weaknesses

Table 71. Novartis Basic Information, Area Served and Competitors

Table 72. Novartis Major Business

Table 73. Novartis Nucleotide-based Therapeutics Product and Services

Table 74. Novartis Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 75. Novartis Recent Developments/Updates

Table 76. Novartis Competitive Strengths & Weaknesses

Table 77. BioNTech Basic Information, Area Served and Competitors

Table 78. BioNTech Major Business

Table 79. BioNTech Nucleotide-based Therapeutics Product and Services

Table 80. BioNTech Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 81. BioNTech Recent Developments/Updates

Table 82. BioNTech Competitive Strengths & Weaknesses

Table 83. Pfizer Basic Information, Area Served and Competitors

Table 84. Pfizer Major Business

Table 85. Pfizer Nucleotide-based Therapeutics Product and Services

Table 86. Pfizer Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 87. Pfizer Recent Developments/Updates

Table 88. Pfizer Competitive Strengths & Weaknesses

Table 89. Moderna Therapeutics Basic Information, Area Served and Competitors

Table 90. Moderna Therapeutics Major Business

Table 91. Moderna Therapeutics Nucleotide-based Therapeutics Product and Services

Table 92. Moderna Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 93. Moderna Therapeutics Recent Developments/Updates

Table 94. Moderna Therapeutics Competitive Strengths & Weaknesses

Table 95. Jazz Pharmaceuticals Basic Information, Area Served and Competitors

Table 96. Jazz Pharmaceuticals Major Business

Table 97. Jazz Pharmaceuticals Nucleotide-based Therapeutics Product and Services

Table 98. Jazz Pharmaceuticals Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 99. Jazz Pharmaceuticals Recent Developments/Updates

Table 100. Jazz Pharmaceuticals Competitive Strengths & Weaknesses

Table 101. CureVac Basic Information, Area Served and Competitors

Table 102. CureVac Major Business

Table 103. CureVac Nucleotide-based Therapeutics Product and Services

Table 104. CureVac Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 105. CureVac Recent Developments/Updates

Table 106. CureVac Competitive Strengths & Weaknesses

Table 107. Regulus Therapeutics Basic Information, Area Served and Competitors

Table 108. Regulus Therapeutics Major Business

Table 109. Regulus Therapeutics Nucleotide-based Therapeutics Product and Services

Table 110. Regulus Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

- Table 111. Regulus Therapeutics Recent Developments/Updates
- Table 112. Regulus Therapeutics Competitive Strengths & Weaknesses
- Table 113. ProQR Basic Information, Area Served and Competitors
- Table 114. ProQR Major Business
- Table 115. ProQR Nucleotide-based Therapeutics Product and Services
- Table 116. ProQR Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 117. ProQR Recent Developments/Updates
- Table 118. ProQR Competitive Strengths & Weaknesses
- Table 119. Secarna Basic Information, Area Served and Competitors
- Table 120. Secarna Major Business
- Table 121. Secarna Nucleotide-based Therapeutics Product and Services
- Table 122. Secarna Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 123. Secarna Recent Developments/Updates
- Table 124. Secarna Competitive Strengths & Weaknesses
- Table 125. MiNA Therapeutics Basic Information, Area Served and Competitors
- Table 126. MiNA Therapeutics Major Business
- Table 127. MiNA Therapeutics Nucleotide-based Therapeutics Product and Services
- Table 128. MiNA Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 129. MiNA Therapeutics Recent Developments/Updates
- Table 130. MiNA Therapeutics Competitive Strengths & Weaknesses
- Table 131. Sylentis Basic Information, Area Served and Competitors
- Table 132. Sylentis Major Business
- Table 133. Sylentis Nucleotide-based Therapeutics Product and Services
- Table 134. Sylentis Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 135. Sylentis Recent Developments/Updates
- Table 136. Sylentis Competitive Strengths & Weaknesses
- Table 137. Arrowhead Basic Information, Area Served and Competitors
- Table 138. Arrowhead Major Business
- Table 139. Arrowhead Nucleotide-based Therapeutics Product and Services
- Table 140. Arrowhead Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 141. Arrowhead Recent Developments/Updates
- Table 142. Arrowhead Competitive Strengths & Weaknesses
- Table 143. Silence Therapeutics Basic Information, Area Served and Competitors
- Table 144. Silence Therapeutics Major Business

- Table 145. Silence Therapeutics Nucleotide-based Therapeutics Product and Services
- Table 146. Silence Therapeutics Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 147. Silence Therapeutics Recent Developments/Updates
- Table 148. Dicerna Basic Information, Area Served and Competitors
- Table 149. Dicerna Major Business
- Table 150. Dicerna Nucleotide-based Therapeutics Product and Services
- Table 151. Dicerna Nucleotide-based Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 152. Global Key Players of Nucleotide-based Therapeutics Upstream (Raw Materials)
- Table 153. Nucleotide-based Therapeutics Typical Customers

LIST OF FIGURE

- Figure 1. Nucleotide-based Therapeutics Picture
- Figure 2. World Nucleotide-based Therapeutics Total Market Size: 2018 & 2022 & 2029, (USD Million)
- Figure 3. World Nucleotide-based Therapeutics Total Market Size (2018-2029) & (USD Million)
- Figure 4. World Nucleotide-based Therapeutics Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
- Figure 5. World Nucleotide-based Therapeutics Revenue Market Share by Region (2018-2029), (by Headquarter Location)
- Figure 6. United States Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
- Figure 7. China Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
- Figure 8. Europe Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
- Figure 9. Japan Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
- Figure 10. South Korea Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
- Figure 11. ASEAN Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
- Figure 12. India Based Company Nucleotide-based Therapeutics Revenue (2018-2029) & (USD Million)
- Figure 13. Nucleotide-based Therapeutics Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 16. World Nucleotide-based Therapeutics Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 18. China Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 23. India Nucleotide-based Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Nucleotide-based Therapeutics by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Nucleotide-based Therapeutics Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Nucleotide-based Therapeutics Markets in 2022

Figure 27. United States VS China: Nucleotide-based Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Nucleotide-based Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Nucleotide-based Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Nucleotide-based Therapeutics Market Size Market Share by Type in 2022

Figure 31. Antisense Oligonucleotides (ASO)

Figure 32. siRNA

Figure 33. mRNA

Figure 34. World Nucleotide-based Therapeutics Market Size Market Share by Type (2018-2029)

Figure 35. World Nucleotide-based Therapeutics Market Size by Application, (USD

Million), 2018 & 2022 & 2029

Figure 36. World Nucleotide-based Therapeutics Market Size Market Share by Application in 2022

Figure 37. Neuromuscular Diseases

Figure 38. hATTR

Figure 39. COVID-19

Figure 40. Other

Figure 41. Nucleotide-based Therapeutics Industrial Chain

Figure 42. Methodology

Figure 43. Research Process and Data Source

I would like to order

Product name: Global Nucleotide-based Therapeutics Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/GB9A17740A80EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB9A17740A80EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970